ADAM10 antibody (APC)
Quick Overview for ADAM10 antibody (APC) (ABIN2656946)
Target
See all ADAM10 AntibodiesReactivity
Host
Clonality
Conjugate
Application
Clone
-
-
Purification
- The antibody was purified by affinity chromatography and conjugated with APC under optimal conditions. The solution is free of unconjugated APC and unconjugated antibody.
-
Isotype
- IgG1 kappa
-
-
-
-
Application Notes
- Optimal working dilution should be determined by the investigator.
-
Restrictions
- For Research Use only
-
-
-
Buffer
- Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide and 0.2 % (w/v) BSA .
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Handling Advice
- Protect from prolonged exposure to light. Do not freeze.
-
Storage
- 4 °C
-
Storage Comment
- The antibody solution should be stored undiluted between 2°C and 8°C
-
-
- ADAM10 (ADAM Metallopeptidase Domain 10 (ADAM10))
-
Alternative Name
- CD156c
-
Background
- CD156c, also known as a disintegrin and metalloproteinase domain-containing protein 10 (ADAM10), is a 748 amino acid type I membrane glycoprotein ubiquitously expressed on most cell types. It consists of multiple functional domains, including a N-terminal prodomain, catalytic domain, cysteine-rich domain, transmembranous domain, and cytoplasmic domain. It is secreted as a precursor protein and becomes as the activate/mature form through removing the ADAM10 prodomain by proprotein convertase 7 and furin. ADAM10 functions as metalloproteinase to cleave several molecules including Notch, pro-TNF-α, amyloid precursor protein, myelin basic protein, and type IV collagen. It mediates the release of several cell adhesion molecules such as vascular endothelial cadherin or L-selectin to regulate endothelial permeability and leukocyte transmigration. Dysregulation of ADAM activity may contribute to the pathogenesis of vascular diseases.
-
Pathways
- Notch Signaling, EGFR Signaling Pathway
Target
-